FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169284238> ?p ?o ?g. }

• W2169284238 endingPage "537" @default.
• W2169284238 startingPage "524" @default.
• W2169284238 abstract "Objective: To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS). Data Sources: A literature search was conducted in MEDLINE (1966–November 2009), International Pharmaceutical Abstracts (1970–November 2009), and EMBASE (1990–November 2009) using the MeSH terms and key words AZD6140, ticagrelor, P2Y12 receptor antagonist, cardiovascular disease, ACS, atherothrombosis, and platelets. Study Selection And Data Extraction: Selected studies evaluated the pharmacology, pharmacokinetics, pharmacodynamics, safety, and efficacy of ticagrelor for the treatment of ACS. Data Synthesis: Ticagrelor selectively and reversibly blocks the P2Y12 receptor, inhibiting platelet aggregation and preventing amplification of platelet activation. Optimal dosing strategy as determined by ticagrelor's pharmacokinetic and pharmacodynamic profile is a loading dose of 180 mg followed by 90 mg by mouth twice daily. At these doses, greater platelet inhibition is observed with ticagrelor as compared to clopidogrel 75 mg once daily in both clopidogrel-experienced and -naïve patients. Studies in patients experiencing ACS concluded that ticagrelor reduced the rate of cardiovascular death, nonfatal myocardial infarction, stent thrombosis, and overall mortality compared to clopidogrel without increasing major bleeding when administered with standard therapy for ACS. There was no significant difference in the risk of stroke with ticagrelor compared to clopidogrel; however, intracranial bleeding was more common with ticagrelor. Ticagrelor is well tolerated; however, minor bleeding, dyspnea, hypotension, nausea, and ventricular pauses were reported more frequently than with clopidogrel. Reversible inhibition with ticagrelor may allow for more rapid surgical intervention after discontinuation, suggesting greater flexibility in treatment of ACS. Conclusions: Ticagrelor's improved pharmacokinetic and pharmacodynamic profile builds upon the limitations of currently available P2Y12 receptor antagonists. Ticagrelor represents a promising approach for the prevention of cardiovascular events in patients with ACS." @default.
• W2169284238 created "2016-06-24" @default.
• W2169284238 creator A5006100621 @default.
• W2169284238 creator A5007330545 @default.
• W2169284238 creator A5068360159 @default.
• W2169284238 creator A5068868063 @default.
• W2169284238 date "2010-02-02" @default.
• W2169284238 modified "2023-09-25" @default.
• W2169284238 title "Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist" @default.
• W2169284238 cites W1553345686 @default.
• W2169284238 cites W158289124 @default.
• W2169284238 cites W1781616672 @default.
• W2169284238 cites W196385150 @default.
• W2169284238 cites W1966493516 @default.
• W2169284238 cites W1971933594 @default.
• W2169284238 cites W1985059672 @default.
• W2169284238 cites W1985598247 @default.
• W2169284238 cites W1994303428 @default.
• W2169284238 cites W1995259829 @default.
• W2169284238 cites W2007957848 @default.
• W2169284238 cites W2017955226 @default.
• W2169284238 cites W2021139116 @default.
• W2169284238 cites W2023365160 @default.
• W2169284238 cites W2024656127 @default.
• W2169284238 cites W2041936661 @default.
• W2169284238 cites W2052741717 @default.
• W2169284238 cites W2053240679 @default.
• W2169284238 cites W2057681387 @default.
• W2169284238 cites W2060258953 @default.
• W2169284238 cites W2063919290 @default.
• W2169284238 cites W2069561061 @default.
• W2169284238 cites W2071093592 @default.
• W2169284238 cites W2072536636 @default.
• W2169284238 cites W2077119701 @default.
• W2169284238 cites W2084673482 @default.
• W2169284238 cites W2087951913 @default.
• W2169284238 cites W2096513204 @default.
• W2169284238 cites W2100209149 @default.
• W2169284238 cites W2105675654 @default.
• W2169284238 cites W2107797912 @default.
• W2169284238 cites W2113513640 @default.
• W2169284238 cites W2126049488 @default.
• W2169284238 cites W2128228188 @default.
• W2169284238 cites W2140501627 @default.
• W2169284238 cites W2143777566 @default.
• W2169284238 cites W2149238031 @default.
• W2169284238 cites W2152804512 @default.
• W2169284238 cites W2159858918 @default.
• W2169284238 cites W2163050713 @default.
• W2169284238 cites W2169387542 @default.
• W2169284238 cites W2768019923 @default.
• W2169284238 cites W4205805944 @default.
• W2169284238 cites W4249225808 @default.
• W2169284238 cites W4376848313 @default.
• W2169284238 doi "https://doi.org/10.1345/aph.1m548" @default.
• W2169284238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20124464" @default.
• W2169284238 hasPublicationYear "2010" @default.
• W2169284238 type Work @default.
• W2169284238 sameAs 2169284238 @default.
• W2169284238 citedByCount "36" @default.
• W2169284238 countsByYear W21692842382012 @default.
• W2169284238 countsByYear W21692842382013 @default.
• W2169284238 countsByYear W21692842382015 @default.
• W2169284238 countsByYear W21692842382016 @default.
• W2169284238 countsByYear W21692842382017 @default.
• W2169284238 countsByYear W21692842382018 @default.
• W2169284238 countsByYear W21692842382019 @default.
• W2169284238 countsByYear W21692842382020 @default.
• W2169284238 countsByYear W21692842382021 @default.
• W2169284238 countsByYear W21692842382023 @default.
• W2169284238 crossrefType "journal-article" @default.
• W2169284238 hasAuthorship W2169284238A5006100621 @default.
• W2169284238 hasAuthorship W2169284238A5007330545 @default.
• W2169284238 hasAuthorship W2169284238A5068360159 @default.
• W2169284238 hasAuthorship W2169284238A5068868063 @default.
• W2169284238 hasConcept C111113717 @default.
• W2169284238 hasConcept C112705442 @default.
• W2169284238 hasConcept C126322002 @default.
• W2169284238 hasConcept C127413603 @default.
• W2169284238 hasConcept C2777028646 @default.
• W2169284238 hasConcept C2777849778 @default.
• W2169284238 hasConcept C2780645631 @default.
• W2169284238 hasConcept C2780890252 @default.
• W2169284238 hasConcept C42219234 @default.
• W2169284238 hasConcept C49059817 @default.
• W2169284238 hasConcept C500558357 @default.
• W2169284238 hasConcept C71924100 @default.
• W2169284238 hasConcept C78519656 @default.
• W2169284238 hasConcept C98274493 @default.
• W2169284238 hasConceptScore W2169284238C111113717 @default.
• W2169284238 hasConceptScore W2169284238C112705442 @default.
• W2169284238 hasConceptScore W2169284238C126322002 @default.
• W2169284238 hasConceptScore W2169284238C127413603 @default.
• W2169284238 hasConceptScore W2169284238C2777028646 @default.
• W2169284238 hasConceptScore W2169284238C2777849778 @default.
• W2169284238 hasConceptScore W2169284238C2780645631 @default.
• W2169284238 hasConceptScore W2169284238C2780890252 @default.
• W2169284238 hasConceptScore W2169284238C42219234 @default.

• next